Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET

Company Participants

Christine Cassiano – Chief Communications Officer

David Chang – President and Chief Executive Officer

Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer

Eric Schmidt – Chief Financial Officer

Conference Call Participants

Tyler Van Buren – Cowen

Salveen Richter – Goldman Sachs

Michael Yee – Jefferies

Kelsey Goodwin – Guggenheim

Ren Benjamin – JMP Securities

Jason Gerberry – Bank of America

Mark Breidenbach – Oppenheimer

David Dai – SMBC

John Newman – Canaccord

Luca Issi – RBC Capital

Raju Prasad – William Blair

Asthika Goonewardene – Truist Securities

Kalpit Patel – B. Riley Securities

Jack Allen – Baird

Operator

Hello, thank you for standing by. And welcome to Allogene Therapeutics Second Quarter of 2022 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Please be aware that today's conference call is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

Thank you, operator, and welcome to our Q2 call. After market closed, we issued a business update and financial result press release for the second quarter of 2022. This press release and today's webcast are available on our website. We ask you to limit your questions to one per person and we'll do our best to get to as many as possible during the hour.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities and 2022 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of the potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements and Allogene disclaims any obligation to update these statements.

I'll now turn the call over to David.

David Chang

Thank you, Christine, and good afternoon. Since our last update, we have continued to make significant progress across our pipeline from our lead CD19 candidate ALLO-501A and our lead BCMA candidate ALLO-715 to our first solid tumor candidate ALLO-316. We believe each of these programs have promising potential and we remain focused on advancing these candidates in a way that will allow us to define, shape and expand the future of cell therapy. This month marks the five year anniversary of the first approval of an autologous CAR T therapy targeting CD19.